Loading clinical trials...
Loading clinical trials...
A Single-arm Multicentre Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Who Have Not Previously Received Therapy for Metastatic Adenocarcinoma of the Pancreas
Conditions
Interventions
Irinotecan liposome injection (S095013)
Oxaliplatin
+2 more
Locations
14
Japan
National Cancer Center Hospital East (003)
Kashiwa, Chiba, Japan
Chiba University Hospital (015)
Chiba, Japan
Chiba Cancer Center (011)
Chiba, Japan
National Hospital Organization Shikoku Cancer Center (013)
Ehime, Japan
National Hospital Organization Kyushu Cancer Center (005)
Fukuoka, Japan
Kanazawa University Hospital (008)
Ishikawa, Japan
Start Date
April 25, 2024
Primary Completion Date
August 28, 2025
Completion Date
January 1, 2026
Last Updated
October 8, 2024
NCT04083235
NCT01654861
Lead Sponsor
Institut de Recherches Internationales Servier
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions